National Cancer Institute (Naples) - Developmental Therapeutics Review - Q1 2011

Global Markets Direct, March 2011, Pages: 53

National Cancer Institute (Naples) – Developmental Therapeutics Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “National Cancer Institute (Naples) – Developmental Therapeutics Review – Q1 2011” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by National Cancer Institute (Naples).
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of National Cancer Institute (Naples) with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of National Cancer Institute (Naples)’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.

Reasons to buy

- Identify new drug targets and therapeutic classes in National Cancer Institute (Naples)’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate National Cancer Institute (Naples)’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of National Cancer Institute (Naples) in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with National Cancer Institute (Naples).
- Avoid Intellectual Property Rights related issues.

List of Tables
List of Figures
National Cancer Institute (Naples) Snapshot
Key Facts
National Cancer Institute (Naples) – Research and Development Overview
Key Therapeutic Areas
National Cancer Institute (Naples) – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
National Cancer Institute (Naples) – Pipeline Products Glance
National Cancer Institute (Naples) – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
National Cancer Institute (Naples) Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
National Cancer Institute (Naples) – Drug Profiles
Carboplatin + Liposomal Doxorubicin
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Etoposide
Product Description
Mechanism of Action
R&D Progress
docetaxel
Product Description
Mechanism of Action
R&D Progress
Doxorubicin + Carboplatin + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
erlotinib + cisplatin + gemcitabine
Product Description
Mechanism of Action
R&D Progress
Gemcitabine
Product Description
Mechanism of Action
R&D Progress
Tarceva + Cisplatin + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
Triptorelin + Letrozole + Zoledronic Acid
Product Description
Mechanism of Action
R&D Progress
cetuximab + gemcitabine
Product Description
Mechanism of Action
R&D Progress
exemestane + lapatinib
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Carboplatin
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Etoposide
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Vinorelbine
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Carboplatin + Cetuximab
Product Description
Mechanism of Action
R&D Progress
Trastuzumab + Docetaxel + Liposomal Doxorubicin + Cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
Vinorelbine + Carboplatin + Trastuzumab
Product Description
Mechanism of Action
R&D Progress
Ziconotide
Product Description
Mechanism of Action
R&D Progress
docetaxel + zoledronic acid
Product Description
Mechanism of Action
R&D Progress
Zometa + Taxotere
Product Description
Mechanism of Action
R&D Progress
National Cancer Institute (Naples) – Pipeline Analysis
National Cancer Institute (Naples) – Pipeline Products by Therapeutic Class
National Cancer Institute (Naples) - Pipeline Products By Target
National Cancer Institute (Naples) – Pipeline Products by Route of Administration
National Cancer Institute (Naples) – Pipeline Products by Molecule Type
National Cancer Institute (Naples) - Dormant Projects
National Cancer Institute (Naples) – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake
• Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players
• Brain Tumor – Pipeline Review, H1 2013
• Oncology Intelligence: A Comprehensive Report for Decision Making
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Molecular Diagnostics in Cancer Testing
• Nausea – Pipeline Review, H1 2013